2019年

November 19, 2019: NHI Drug Price Listing and Release of Oral Quinolone Antibacterial Agent "Lasvic®Tablets 75mg"
November 7, 2019: Summary of Consolidated Financial Results (For the Second Quarter Ended September 30, 2019) [Japanese Standard]
November 7, 2019: Second Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2020 - Supplementary Information
November 7, 2019: The Revision of Consolidated Financial Forecasts for Fiscal Year Ending March 31, 2020
November 7, 2019: Absorption-type Merger between the Consolidated Subsidiaries
November 7, 2019: KYORIN and JEIL Signed License Agreement for Vibegron in Korea
November 5, 2019: Revision of Consolidated Financial Forecasts
October 29, 2019: Release of Microchannel-based Genetic Measurement Device GeneSoC®
October 28, 2019: Resumption of Supply of Desalex® Tablets 5mg Long-Acting Selective H1 Receptor Antagonist for Allergic Diseases Treatment
September 20, 2019: Kyorin Pharmaceutical Receives Marketing Approval for Oral Quinolone Antibacterial Agent "Lasvic®Tablets 75mg"
August 23, 2019: Release of Mometasone Nasal 50μg「KYORIN」56sprays, 112sprays
July 31, 2019: Summary of Consolidated Financial Results(July 31,2019)
July 31, 2019: First Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2020
May 14, 2019: Financial Results for Fiscal 2018
May 13, 2019: Summary of Consolidated Financial Results (For the fiscal year ended March 31, 2019) [Japanese Standard]
May 13, 2019: Consolidated Financial Results for the Fiscal Year Ending March 31, 2019
May 13, 2019: Kyorin Signed Memorandum of Understanding on Marketing Collaboration with respect to Chronic Cough Treatment
April 2, 2019: Release of Alcohol-Free Hand Sanitizer Noahtect® Pro
March 27, 2019: Conclusion of Agreement on OTC Drug Marketing Rights with DER UAW PHARMACEUTICAL CO., LTD.
March 27, 2019: Conclusion of Agreement with Monospharm Trade Co., Ltd. Concerning Marketing Rights for Generic Medicines
February 5, 2019: Summary of Consolidated Financial Results (For the Third Quarter Ended Dec 31, 2018) [Japanese Standard]
February 5, 2019: Third Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2019 - Supplementary Information
February 5, 2019: The Revision of Consolidated Financial Forecasts for Fiscal Year Ending March 31, 2019
January 7, 2019: Impact on Kyorin's Financial Performance of MSD's Decision to Voluntarily Recall Desalex® Tablets 5mg Long-Acting Selective H1 Receptor Antagonist for Allergic Diseases Treatment